ATARA BIOTHERAPEUTICS, INC. Available-for-sale Securities, Amortized Cost Basis
ATARA BIOTHERAPEUTICS, INC. (ATRA) had Available-for-sale Securities, Amortized Cost Basis of $164.79 million as of 2017-12-31, per its 10-K filed 2018-02-27.
Discontinued › Notes › Investments
us-gaap:AvailableForSaleSecuritiesAmortizedCost · last filed 2018-02-27
- 2017-12-31: Available-for-sale Securities, Amortized Cost Basis $164.79M.
- 2016-12-31: Available-for-sale Securities, Amortized Cost Basis $245.84M.
- 2015-12-31: Available-for-sale Securities, Amortized Cost Basis $319.51M.
- 2015-09-30: Available-for-sale Securities, Amortized Cost Basis $279.75M.
| Period end | Available-for-sale Securities, Amortized Cost Basis |
|---|---|
| 2017-12-31 | $164.79M 10-K · filed 2018-02-27 |
| 2016-12-31 | $245.84M 10-K · filed 2018-02-27 |
| 2015-12-31 | $319.51M 10-K · filed 2017-03-09 |
| 2015-09-30 | $279.75M 10-Q · filed 2015-11-06 |
| 2015-06-30 | $128.91M 10-Q · filed 2015-08-07 |
| 2015-03-31 | $95.39M 10-Q · filed 2015-05-11 |
| 2014-12-31 | $82.32M 10-Q · filed 2015-11-06 |
| 2014-09-30 | $26.01M 10-Q · filed 2014-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |